Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.
Clinical Stage Pharma
Developing small molecules for the treatment of gastric acid related diseases.
Cinclus Pharma
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.
Our lead asset
Linaprazan glurate
Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.
In the spotlight
We develop the future GERD treatment which has roots in AstraZeneca
Highlights from the 2024 Annual Report: Interview with the founders. Cinclus Pharma, founded by a team of experts with deep roots in the pharmaceutical industry, is on a mission to bring an effective GERD treatment, linaprazan glurate, to the market…
A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Nina Rawal, Trill Impact Ventures, on the investment in Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with Nina Rawal. Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures…
"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective P-CAB linaprazan glurate and making it available worldwide."
CHRISTER AHLBERG
CEO CINCLUS PHARMA